Alnylam Pharma is said to be a potential target for Novartis - Bloomberg

JHVEPhoto/iStock Editorial via Getty Images

• Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis (NYSE:NVS) as investor push for the drugmaker to make an acquisition and use its cash. Alnylam rose 4.2% in premarket trading.
• Alnylam, with a market cap of more than $20B could be a possible acquisition candidate, according to a Bloomberg report, which cited people familiar.
• Novartis declined to comment to Bloomberg on potential acquisitions.
• Alnylam (ALNY) was likely also on the the mover after Novo Nordisk (NYSE:NVO) agreed to acquire Dicerna (NASDAQ:DRNA) for more than $3B. ALNY is focused on RNAi therapies, similar to Dicerna.
• Earlier this month, Intellia Therapeutics, Alnylam seen as potential Regeneron (NASDAQ:REGN) targets, analyst says. Benchmark analyst Aydin Huseynov wrote that ALNY would likely be worth more than $30B in an acquisition.

Comments

[knowsstox]

ALNY has rapidly growing revenues, a great RNAi platform for drug development and great data on a potentially game changing therapy for hypertension. Plus NVS will save billions by not having to pay inclisiran royalties to ALNY. Impending buyout may explain Alnylam CEO’s John Maraganore surprising retirement plans. I sense there may be something to this.

[rudyel]

haa haa just another rumor and bust!

[dom_biotech]

@rudyel 😂😂😂

[chrloe]

If Novartis were economically savvy they'd go for VRTX instead. Next year's economic bust will be all about having US dollars or not. Not much use adding an EPS negative company to their assets.

[stevevai1983]

@chrloe VRTX is too expensive for a buy out. You must prepare something like 70B.

[knowsstox]

@stevevai1983 your math is way way way way off. $70 billion would be around $600 per share. Nobody is talking anything in that price range.

[knowsstox]

@stevevai1983 sorry, thought you were talking about ALNY.

[settembrini007]

ALNY would be another bad acquisition for Novartis. Translation: they might actually do it to fail again.

[Pharma95410]

@settembrini007 Bad because they have best in class platform technology? Or because every drug they try and launch smashes clinical expectations?